vs
Side-by-side financial comparison of QuidelOrtho Corp (QDEL) and ZILLOW GROUP, INC. (ZG). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($699.9M vs $654.0M, roughly 1.1× ZILLOW GROUP, INC.). ZILLOW GROUP, INC. runs the higher net margin — 0.5% vs -104.7%, a 105.2% gap on every dollar of revenue. On growth, ZILLOW GROUP, INC. posted the faster year-over-year revenue change (18.1% vs -3.7%). ZILLOW GROUP, INC. produced more free cash flow last quarter ($44.0M vs $-94.7M). Over the past eight quarters, ZILLOW GROUP, INC.'s revenue compounded faster (11.2% CAGR vs -2.9%).
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
Zillow Group, Inc., or simply Zillow, is an American tech real-estate marketplace company that was founded in 2006 by co-executive chairmen Rich Barton and Lloyd Frink, former Microsoft executives and founders of Microsoft spin-off Expedia; Spencer Rascoff, a co-founder of Hotwire.com; David Beitel, Zillow's current chief technology officer; and Kristin Acker, Zillow's current technology leadership advisor.
QDEL vs ZG — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $699.9M | $654.0M |
| Net Profit | $-733.0M | $3.0M |
| Gross Margin | — | 72.8% |
| Operating Margin | -100.7% | -1.7% |
| Net Margin | -104.7% | 0.5% |
| Revenue YoY | -3.7% | 18.1% |
| Net Profit YoY | -3583.4% | 105.8% |
| EPS (diluted) | $-10.78 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $654.0M | ||
| Q3 25 | $699.9M | $676.0M | ||
| Q2 25 | $613.9M | $655.0M | ||
| Q1 25 | $692.8M | $598.0M | ||
| Q4 24 | $707.8M | $554.0M | ||
| Q3 24 | $727.1M | $581.0M | ||
| Q2 24 | $637.0M | $572.0M | ||
| Q1 24 | $711.0M | $529.0M |
| Q4 25 | — | $3.0M | ||
| Q3 25 | $-733.0M | $10.0M | ||
| Q2 25 | $-255.4M | $2.0M | ||
| Q1 25 | $-12.7M | $8.0M | ||
| Q4 24 | $-178.4M | $-52.0M | ||
| Q3 24 | $-19.9M | $-20.0M | ||
| Q2 24 | $-147.7M | $-17.0M | ||
| Q1 24 | $-1.7B | $-23.0M |
| Q4 25 | — | 72.8% | ||
| Q3 25 | — | 72.6% | ||
| Q2 25 | — | 74.7% | ||
| Q1 25 | — | 76.8% | ||
| Q4 24 | — | 75.8% | ||
| Q3 24 | — | 75.9% | ||
| Q2 24 | — | 77.3% | ||
| Q1 24 | — | 76.7% |
| Q4 25 | — | -1.7% | ||
| Q3 25 | -100.7% | -0.4% | ||
| Q2 25 | -29.4% | -1.7% | ||
| Q1 25 | 4.7% | -1.5% | ||
| Q4 24 | -14.2% | -12.5% | ||
| Q3 24 | 2.1% | -7.7% | ||
| Q2 24 | -18.4% | -6.6% | ||
| Q1 24 | -247.3% | -8.5% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | -104.7% | 1.5% | ||
| Q2 25 | -41.6% | 0.3% | ||
| Q1 25 | -1.8% | 1.3% | ||
| Q4 24 | -25.2% | -9.4% | ||
| Q3 24 | -2.7% | -3.4% | ||
| Q2 24 | -23.2% | -3.0% | ||
| Q1 24 | -239.9% | -4.3% |
| Q4 25 | — | $0.01 | ||
| Q3 25 | $-10.78 | $0.04 | ||
| Q2 25 | $-3.77 | $0.01 | ||
| Q1 25 | $-0.19 | $0.03 | ||
| Q4 24 | $-2.54 | $-0.23 | ||
| Q3 24 | $-0.30 | $-0.08 | ||
| Q2 24 | $-2.20 | $-0.07 | ||
| Q1 24 | $-25.50 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $98.1M | $768.0M |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $2.0B | $4.9B |
| Total Assets | $5.7B | $5.7B |
| Debt / EquityLower = less leverage | 1.23× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $768.0M | ||
| Q3 25 | $98.1M | $874.0M | ||
| Q2 25 | $151.7M | $587.0M | ||
| Q1 25 | $127.1M | $914.0M | ||
| Q4 24 | $98.3M | $1.1B | ||
| Q3 24 | $143.7M | $1.1B | ||
| Q2 24 | $107.0M | $1.2B | ||
| Q1 24 | $78.5M | $1.4B |
| Q4 25 | — | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $2.2B | — |
| Q4 25 | — | $4.9B | ||
| Q3 25 | $2.0B | $5.0B | ||
| Q2 25 | $2.8B | $4.7B | ||
| Q1 25 | $3.0B | $4.8B | ||
| Q4 24 | $3.0B | $4.8B | ||
| Q3 24 | $3.2B | $4.7B | ||
| Q2 24 | $3.2B | $4.5B | ||
| Q1 24 | $3.3B | $4.7B |
| Q4 25 | — | $5.7B | ||
| Q3 25 | $5.7B | $5.7B | ||
| Q2 25 | $6.4B | $5.4B | ||
| Q1 25 | $6.5B | $5.7B | ||
| Q4 24 | $6.4B | $5.8B | ||
| Q3 24 | $6.8B | $6.2B | ||
| Q2 24 | $6.7B | $6.6B | ||
| Q1 24 | $6.7B | $6.8B |
| Q4 25 | — | — | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.72× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.68× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-45.5M | $72.0M |
| Free Cash FlowOCF − Capex | $-94.7M | $44.0M |
| FCF MarginFCF / Revenue | -13.5% | 6.7% |
| Capex IntensityCapex / Revenue | 7.0% | 4.3% |
| Cash ConversionOCF / Net Profit | — | 24.00× |
| TTM Free Cash FlowTrailing 4 quarters | $-153.1M | $235.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $72.0M | ||
| Q3 25 | $-45.5M | $105.0M | ||
| Q2 25 | $-46.8M | $87.0M | ||
| Q1 25 | $65.6M | $104.0M | ||
| Q4 24 | $63.7M | $122.0M | ||
| Q3 24 | $117.9M | $171.0M | ||
| Q2 24 | $-97.9M | $55.0M | ||
| Q1 24 | $-700.0K | $80.0M |
| Q4 25 | — | $44.0M | ||
| Q3 25 | $-94.7M | $73.0M | ||
| Q2 25 | $-84.3M | $50.0M | ||
| Q1 25 | $9.4M | $68.0M | ||
| Q4 24 | $16.5M | $88.0M | ||
| Q3 24 | $71.4M | $138.0M | ||
| Q2 24 | $-133.2M | $18.0M | ||
| Q1 24 | $-66.8M | $41.0M |
| Q4 25 | — | 6.7% | ||
| Q3 25 | -13.5% | 10.8% | ||
| Q2 25 | -13.7% | 7.6% | ||
| Q1 25 | 1.4% | 11.4% | ||
| Q4 24 | 2.3% | 15.9% | ||
| Q3 24 | 9.8% | 23.8% | ||
| Q2 24 | -20.9% | 3.1% | ||
| Q1 24 | -9.4% | 7.8% |
| Q4 25 | — | 4.3% | ||
| Q3 25 | 7.0% | 4.7% | ||
| Q2 25 | 6.1% | 5.6% | ||
| Q1 25 | 8.1% | 6.0% | ||
| Q4 24 | 6.7% | 6.1% | ||
| Q3 24 | 6.4% | 5.7% | ||
| Q2 24 | 5.5% | 6.5% | ||
| Q1 24 | 9.3% | 7.4% |
| Q4 25 | — | 24.00× | ||
| Q3 25 | — | 10.50× | ||
| Q2 25 | — | 43.50× | ||
| Q1 25 | — | 13.00× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
ZG
| Residential Revenue | $418.0M | 64% |
| Rental Revenue | $168.0M | 26% |
| Mortgage Revenue | $57.0M | 9% |
| Display Advertising And Other Revenue | $11.0M | 2% |
